Aesthetic and dermatological device brand Cutera has announced the UK and Ireland release of its laser device, AviClear.
The device had a strong rollout in the US and Canada, creating high anticipation for its introduction on this side of the pond.
AviClear is the first FDA-cleared laser for long-term treatment of inflammatory acne vulgaris, selectively targeting and supressing the sebaceous glands to eliminate acne at the source. Research carried out by Cutera found nine out of 10 patients have been satisfied or very satisfied with their results.
“We are excited to be offering this ground-breaking AviClear treatment to physicians and patients in the UK and Ireland,” said Sam Keene, Cutera regional leader UK and Ireland, “Based on feedback from our early adopters, we are confident that patient demand and clinic installations will continue to grow over the next few months and that the affordability, efficacy, and durability of AviClear will establish it as the gold standard of care for acne sufferers.”
Cutera is hosting an AviClear symposium at the International Master Course on Aging Science (IMCAS) conference, with a global panel of key opinion leaders discussing AviClear clinical data and in-practice outcomes. The panel will outline the trial results underpinning the FDA clearances, alongside their own in-clinic experiences.
